Related Experiment Video
Updated: Aug 8, 2026

Isolating Lymphocytes from the Mouse Small Intestinal Immune System
Published on: February 28, 2018
CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance
Jai Hyang Go1, Woo Ick Yang, Howe J Ree
1Department of Pathology, Dankook University College of Medicine, Cheonan-si, Chungchungnam-do, Korea.
Insights
Over half of primary intestinal large B-cell lymphomas originate from germinal center B cells. CD10 expression in these lymphomas may indicate a better prognosis and treatment response.
Area of Science:
- Oncology
- Immunohistochemistry
- Gastrointestinal Pathology
Background:
- Primary intestinal large B-cell lymphomas (PILBCL) are a heterogeneous group of tumors.
- Understanding the cellular origin of PILBCL is crucial for accurate diagnosis and prognosis.
Purpose of the Study:
- To investigate the prevalence of a germinal center B-cell origin in PILBCL using CD10 expression.
- To assess the clinical significance and prognostic value of CD10 expression in PILBCL.
Main Methods:
- Immunohistochemistry was used to detect CD10 and Bcl-6 expression in 32 surgically resected PILBCL tissue samples.
- CD10 protein expression was correlated with clinical parameters, including disease stage, treatment response, and survival.
Main Results:
- 47% of PILBCL cases were CD10 positive, often co-expressing Bcl-6.
- CD10 positive lymphomas were more frequently diagnosed at an earlier stage (Stage I2) and showed a significantly better response to treatment.
- A trend towards longer overall survival was observed in CD10 positive cases, though not statistically significant.
Conclusions:
- A significant proportion of PILBCL cases appear to originate from germinal center B cells.
- CD10 expression is a potential prognostic biomarker for patients with primary intestinal large B-cell lymphomas, indicating a favorable outcome.
Objective:
To determine the prevalence and clinical significance of a follicular origin in primary intestinal large B-cell lymphomas.
Design:
We performed immunohistochemistry for detection of CD10 and Bcl-6 in paraffin-embedded tissue sections from 32 patients who had surgically resected primary intestinal lymphomas. We then correlated the expression of CD10 protein with various clinical parameters.
Results:
Fifteen of 32 cases (47%) were CD10(+), and CD10 positivity was correlated with intense Bcl-6 positivity. There were no significant differences in age, sex, serum lactate dehydrogenase level, and performance status between the CD10(+) and CD10(-) groups. Patients with CD10(+) lymphoma more frequently presented with stage I(2) disease compared with those with CD10(-) lymphoma (P =.03). The response to treatment was significantly better in the CD10(+) group than in the CD10(-) group (P =.02). An analysis of survival rates showed a trend for a longer overall survival duration in the CD10(+) group compared with the CD10(-) group, although this was not statistically significant (P =.05).
Conclusions:
We propose that more than half of primary intestinal large B-cell lymphomas have a germinal center cell origin. We also suggest that CD10 expression may be a prognostic indicator in patients with primary intestinal large B-cell lymphomas.
Related Concept Videos
Renewal of Intestinal Stem Cells
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

